Posted by Michael Wonder on 21 Aug 2017
AbbVie’s Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes
17 August 2017 - Maviret is the first and only 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment.
AbbVie today announced that Health Canada has granted approval for Maviret (glecaprevir/pibrentasvir tablets), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes.
The efficacy and safety of Maviret was evaluated in nine Phase 2-3 clinical trials, in over 2,300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).
